Highlights on this Page

Webinar Details

  • Pub Code: C2P08-11WEB
  • Speakers
    • Marcus D. Wilson, Pharm.D.
    • Brian Sweet, B.S. Pharm., M.B.A.

3 Easy Ways to Order

  1. Secure Shopping Cart
  2. Call 800-521-4323
  3. Print a form to fax or mail

Generating Real-World Evidence for Formulary Development: Health Plan Strategies and Results

February 16, 2012 Webinar - Listen On-Demand or Get a CD!

Comparative-effectiveness research (CER) has been gaining ground as health plans seek to provide optimal patient care through evidence-based decisions. The federal government has recognized the importance of CER with the establishment of a national data clearinghouse and funding of other research activities, but it has not yet delivered the evidence that payers are seeking. As a result, insurers and PBMs are conducting their own real-world evidence studies to determine which drug therapies provide the best health outcomes and are the most cost efficient. Find out what innovative steps two industry leaders have taken to generate real-world data to develop better drugs and help payers make outcomes-based formulary decisions.

Place your order through our secure shopping cart

$329.00
$329.00

The On-Demand recording will be available immediately upon purchase* as a link within a PDF file of the accompanying written materials. CDs and printed materials are shipped via USPS.

Sponsored by Atlantic Information Services, Inc., publisher of Drug Benefit News, Specialty Pharmacy News and Health Plan Week

More than half of the new drugs approved by the FDA during the past decade have been accompanied by some form of comparative-effectiveness data from clinical trials. But health plan experts often discount the study design, the lack of full category comparisons or the data’s ability to be applied to the real world and help payers determine which therapies deserve preferred status. While randomized controlled trials continue to be the gold standard, managed care experts are increasingly recognizing the value of supplemental real-world data in helping them to make formulary decisions. And although more than $1.1 billion in ARRA funds have been earmarked for CER and the health reform law established the Patient-Centered Outcomes Research Institute, plans can’t afford to wait for new data.

As a result, health plans and PBMs alike are teaming up with pharmaceutical companies to perform their own CER to determine the therapies in various categories that have the most value for payers. For example, HealthCore, Inc., the health outcomes research subsidiary of WellPoint, Inc., and AstraZeneca Pharmaceuticals LP have pooled their resources to conduct real-world studies aimed at determining how to most effectively and economically treat disease, with special emphasis on chronic illnesses. Unlike controlled clinical trials, real-world evidence studies use observational data such as electronic medical records, claims information and patient surveys.

Listen in as top executives from HealthCore and AstraZeneca demonstrate how these two companies have collaborated to deliver real-world evidence to payers. You’ll get insider perspectives on key questions such as:

  • How are health plans using real-world evidence today? With what results?
  • How can these data be used to improve the quality of health care and reduce costs?
  • What methods can health plans use to generate real-world evidence?
  • Which therapeutic conditions would benefit from these data the most?
  • What are the most important lessons learned so far from the HealthCore-AstraZeneca collaboration?

Speakers

MARCUS D. WILSON, Pharm.D., is president of HealthCore, WellPoint’s wholly owned outcomes research subsidiary. Dr. Wilson received his Bachelor of Science in Biochemistry from Virginia Tech and his Doctor of Pharmacy degree from the Medical College of Virginia. Dr. Wilson serves as a member of the FDA Mini-Sentinel Program’s Project Operations Council, the Brookings Active Safety Surveillance Council, the Observational Medical Outcomes Partnership Executive Board, the Board of Visitors for the Mayes College of Healthcare Business & Policy at the University of Sciences in Philadelphia and the 2020 Vision Task Force for the International Society of Pharmacoeconomics and Outcomes Research (ISPOR). He is a past member of the Board of Directors for ISPOR and is a reviewer for multiple journals.

BRIAN SWEET, B.S. Pharm., M.B.A., is executive director, healthcare alliances, at AstraZeneca. Mr. Sweet is focused on AstraZeneca’s initiatives in real-world evidence and comparative-effectiveness research and collaborating with health plans, pharmacy benefit managers and a variety of key business partners. In addition, he coordinates with managed markets customers on the development of performance-driven models, health improvement programs, value-based insurance designs and evolving health care reform issues. Mr. Sweet is the former chief pharmacy officer of WellPoint. He was responsible for overseeing all clinical pharmacy services at WellPoint including leading the National Pharmacy and Therapeutics Committee, which uses integrated data analyses and total cost of care modeling to improve patient health outcomes. In addition, he oversaw the development of strategic pharmacy alliances with academia, government, health organizations and pharmaceutical companies for the purpose of working together to promote the effective and appropriate use of drugs in the communities that WellPoint serves. Mr. Sweet provided strategic leadership for establishing enterprise pharmacy programs as an integral part of the organization in developing corporate pharmacy policy and innovative pharmacy benefit designs. He was also responsible for influencing public policy by communicating with media, analysts, professional organizations, members and providers to provide: public policy, legislative and media responses related to pharmacy coverage, benefits, medication management, the WellPoint Outcomes-Based Formulary application and specialty pharmacy initiatives.

Moderator: Lauren Flynn Kelly, editor of AIS's Drug Benefit News

Designed Especially For

Pharmacy, clinical services and medical directors; strategic planners; product development, contracting and marketing executives; and financial and operations executives at

  • Health plans
  • Specialty pharmacies
  • PBMs and pharmacy benefit administrators
  • Pharmaceutical manufacturers
  • Employers
  • Group-purchasing organizations
  • Physician groups
  • Consulting firms
  • Disease management companies
  • Third-party administrators

Shipping Information

CDs (and accompanying written materials) are shipped via UPS. Please give us your street address when you order (UPS does not deliver to PO boxes). You should receive your order within two weeks.* Shipping and handling cost is $12.

The On-Demand Recording will be delivered as a link within a PDF file of the accompanying written materials. Shipping will NOT be charged for this item.

  • If you order the On-Demand Recording before the conference date (by itself or in combination with the live Webinar), you will be sent an e-mail with the PDF file attached once the recording is available.*
  • After the On-Demand Recording is available*, if you order on this website through our secure shopping cart, you will receive an e-mail, immediately after submitting your order, with a link directing you to download the PDF file. If you order through our customer service department (by phone, mail, fax or e-mail), you will be sent an e-mail with the PDF file attached.

Rush Orders: Please call us at 800-521-4323 to place a rush order.* We will overnight your order for an additional charge of $30, or you can give us your FedEx or UPS account number and we will charge the shipping to your account. Rush orders placed after 3:00pm EST will not be shipped out until the next business day.

*On-Demand recordings will be available within a week of the conference and CDs will be available within two weeks.

Written Materials

Listeners will also receive practical written information to supplement information covered by the Webinar speakers. A copyright release in the Printed Materials will permit you to make photocopies for each person listening to the Webinar and/or the On-Demand Recording.

Generating Real-World Evidence for Formulary Development: Health Plan Strategies and Results

Place your order through our secure shopping cart

$329.00
$329.00

MarketPlace Search

View All AIS Products By

Missed a Live Event?

Listen at your convenience to recent webinars with On-Demand or CD options!

Renewal Center

Renew your subscriptions to AIS newsletter and looseleaf publications at the Renewal Center